Balsm Alofoq Medical (9620) Fundamentals 2026 — P/E 25.8x, Revenue Analysis | SniperIQ
Balsm Alofoq Medical (9620) is a SA-listed Healthcare company in Medical - Equipment & Services with a market capitalization of SAR 59M, trading at SAR 23.50 on the SAU. This SniperIQ fundamentals page covers Balsm Alofoq Medical's valuation (P/E 25.8x, P/B 1.9x), profitability (net margin 8.9%), revenue (SAR 20M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Balsm Alofoq Medical's market cap?
Balsm Alofoq Medical (9620) has a market capitalization of approximately SAR 59M, trading at SAR 23.50 on the SAU. Market cap moves with the live share price.
What is Balsm Alofoq Medical's P/E ratio?
Balsm Alofoq Medical's trailing twelve-month P/E ratio is 25.8x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Balsm Alofoq Medical?
Balsm Alofoq Medical runs a net profit margin of 8.9%, a gross margin of 37.2%, and an operating margin of 12.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Balsm Alofoq Medical generate?
Balsm Alofoq Medical reported revenue of SAR 20M for fiscal year 2025, with net income of SAR 2M and earnings per share (EPS) of 0.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Balsm Alofoq Medical pay a dividend?
Balsm Alofoq Medical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Balsm Alofoq Medical financially healthy?
Balsm Alofoq Medical carries a debt-to-equity ratio of 0.05x and a current ratio of 10.26x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Balsm Alofoq Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Balsm Alofoq Medical (9620) the key facts are: market cap SAR 59M, P/E 25.8x, revenue SAR 20M, 52-week range 22-37.95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Balsm Alofoq Medical's full fundamentals live
Get Balsm Alofoq Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.